admabio.com

What admabio.com does

ADMA Biologics, Inc. is a US-domiciled, vertically integrated specialty biopharmaceutical company that develops, manufactures, and commercializes plasma-derived immune globulin (IVIG) biologics for immune-compromised patients. Founded in 2007 and publicly traded on NASDAQ under ticker ADMA since 2013, the company markets three FDA-approved products: ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), a hyperimmune IVIG with standardized high titers of neutralizing antibodies to RSV and other respiratory pathogens; BIVIGAM (Immune Globulin Intravenous, Human 10% Liquid), a standard IVIG; and Nabi-HB (Hepatitis B Immune Globulin, Human). The company holds a patent portfolio (US 9,107,906; 9,714,283; 9,815,886, expiring 2035) covering ASCENIV composition, use, and methods, anchored by a proprietary microneutralization assay used to identify high-titer plasma donors and construct tailored hyperimmune plasma pools.

ADMA operates an end-to-end production stack that includes seven ADMA BioCenters plasma collection centers supplying source plasma and an FDA-licensed Boca Raton, Florida manufacturing facility with approximately 600,000 L of annual plasma fractionation and purification capacity. Manufacturing incorporates solvent-detergent viral inactivation, chromatography purification, and aseptic fill-finish using a Cytiva SA25 gloveless robotic isolator with vaporized hydrogen peroxide sterilization. In addition to proprietary product sales, ADMA offers contract manufacturing (CDMO) services — clinical-stage and commercial aseptic filling and packaging for external pharma and biotech clients — and operates the ADMAlytics AI platform, built on TCG Digital's tgcmcube, for biopharmaceutical manufacturing optimization.

The commercial business targets US healthcare providers (allergists, immunologists, infectious disease specialists), hospitals, infusion centers, specialty pharmacies, and patients with primary immunodeficiency and other immune-compromised conditions, reaching an estimated 250,000 US PI patients through specialty pharmaceutical distribution, direct field sales, and the ADMA ADvantage patient support hub. The company is led by founder and CEO Adam S. Grossman (in role since October 2011), who has overseen more than $1.5 billion in cumulative equity and debt financings and the 2017 asset acquisition of the Biotest Therapy Business Unit that established its vertical integration.

Name

admabio.com

Legal name

ADMA Biologics, Inc.

Website

https://admabio.com

Company type

Public

Founded year

2007

Operating status

Operating

Short description

ADMA Biologics is a US-based, vertically integrated specialty biopharmaceutical company that develops, manufactures, and commercializes FDA-approved plasma-derived immune globulin products (ASCENIV, BIVIGAM, Nabi-HB) and contract manufacturing services for healthcare providers and patients with primary immunodeficiency.

Ownership category

akta.pro rank

Product category

Plasma-Derived Biologics Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Plasma-derived biologics
• Immune globulin products
• Biopharmaceutical manufacturing
• Contract manufacturing services
• Plasma collection services

Headquarters

HQ city

Ramsey

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Specialty Biologics Product Sales: Sale of FDA-approved immune globulin products including ASCENIV, BIVIGAM, and Nabi-HB to healthcare providers, hospitals, infusion centers, and specialty pharmacies for treatment of primary immunodeficiency and hepatitis B.
2. Contract Manufacturing (CDMO): Provides clinical-stage and commercial aseptic filling and final packaging services to external pharmaceutical and biotech clients through its FDA-approved manufacturing facility with excess capacity.
3. Plasma Collection Services: Collection and supply of source plasma through ADMA BioCenters network for internal manufacturing use and potential external supply.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

ADMA Biologics is an end-to-end, vertically integrated commercial biopharmaceutical company that develops, manufactures, and markets FDA-approved specialty plasma-derived immune globulin (IVIG) biologic therapies — ASCENIV, BIVIGAM, and Nabi-HB — for patients with primary immunodeficiency and hepatitis B. The company also operates ADMA BioCenters for source plasma collection and offers third-party contract manufacturing (CDMO) aseptic fill-finish services leveraging its FDA-licensed Boca Raton manufacturing facility.

Product overview

ADMA Biologics is an end-to-end commercial biopharmaceutical company with three FDA-approved immune globulin products: ASCENIV™ (Immune Globulin Intravenous, Human – slra), a unique hyperimmune product with high titers to RSV and respiratory pathogens; BIVIGAM® (Immune Globulin Intravenous, Human), a standard 10% liquid IVIG product; and Nabi-HB® (Hepatitis B Immune Globulin, Human), a hyperimmune product for hepatitis B. The company also offers contract manufacturing and development organization (CDMO) services including aseptic fill-finish capabilities, leveraging its patented immunotechnology platform that screens and identifies high-titer plasma donors to create tailored plasma pools with elevated antibody levels to specific pathogens.

Differentiator

Problem solved

Functional benefit

Brands

• ASCENIV: Immune Globulin Intravenous (Human), slra 10% Liquid - FDA-approved immune globulin product
• BIVIGAM
• Nabi-HB
• ADMA BioCenters
• ADMAlytics

Products and services

• ASCENIV (Immune Globulin Intravenous, Human – slra) FDA-approved immune globulin intravenous product containing a unique blend of high-titer immune globulin with standardized levels of neutralizing antibodies to respiratory syncytial virus (RSV) and other respiratory pathogens; indicated for treatment of primary immunodeficiency in patients requiring passive immunity.
• BIVIGAM (Immune Globulin Intravenous, Human, 10% Liquid) FDA-approved 10% liquid immune globulin intravenous product indicated for treatment of primary immunodeficiency and other immune compromised patient populations requiring IgG replacement therapy.
• Nabi-HB (Hepatitis B Immune Globulin, Human) FDA-approved hepatitis B immune globulin product indicated for treatment and post-exposure prophylaxis of hepatitis B infection.
• Contract Manufacturing (CDMO) – Aseptic Fill-Finish Services Clinical-stage and commercial aseptic fill-finish and final packaging services offered to external pharmaceutical and biotech clients through ADMA's FDA-approved manufacturing facility with excess capacity, including Cytiva SA25 robotic gloveless isolator technology.
• ADMA BioCenters Plasma Collection Services Source plasma collection through a network of plasma collection centers operating under the corporate umbrella, supplying raw material plasma for internal manufacturing of ADMA's immune globulin products.
• ADMA ADvantage Ig Patient Support Program Patient support hub program that helps eligible patients maximize insurance benefits, locate alternative funding, and access payment options; supports providers and staff with benefits verification, claims, and reimbursement support for ADMA's IVIG products.

Quantifiable outcome

• High-titer IVIG 10% (human)-slra reduces infections and hospitalizations over 6 to 12 months in retrospective quality improvement study
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Sanofi: Diversified global biopharmaceutical company with a specialty care plasma and immunology franchise (previously Bioverativ, Genzyme). Competes with ADMA's IVIG/hyperimmune portfolio through larger immunology and rare disease infrastructure.
• Emergent BioSolutions: Specialty biopharmaceutical company with plasma-derived therapies (e.g., VIGIV, WinRho) and broader biodefense/government portfolio. Less direct IVIG overlap but comparable specialty biologics/CDMO positioning and government channel exposure.
• Pfizer: Global biopharmaceutical incumbent with broad specialty/biologics portfolio and historical plasma-derived exposure through prior collaborations. Competes indirectly with ADMA for hospital/infusion channel real estate and specialty biologics distribution.

Direct peers

• Grifols: Global plasma-derived therapies leader with the world's largest plasma collection network (300+ centers), competing head-to-head with ADMA in IVIG (Gamunex, Flebogamma), hyperimmune, and albumin. Most direct comparable on product, business model, and end markets.
• CSL Behring: Plasma therapies arm of CSL Limited, marketing Privigen (IVIG), Hizentra (SCIG), and HyperHEP B (hepatitis B immune globulin) — directly overlapping with ASCENIV, BIVIGAM, and Nabi-HB. Comparable vertical integration from plasma collection through commercial biologic distribution.
• Octapharma: Privately held Swiss plasma-derived therapies company with Octagam (IVIG) and Gammanorm (SCIG). Competes in the same IVIG indication, same hospital/infusion channel, with a vertically integrated plasma collection network comparable in structure to ADMA.
• Bio Products Laboratory (BPL): UK-headquartered plasma product manufacturer (Gammaplex IVIG, HyperHEP B, Coagadex). Direct competitor in IVIG and hepatitis B immune globulin categories with similar scale to ADMA and a focus on specialty plasma-derived biologics.
• Takeda Pharmaceutical: Inherited Shire/Baxalta's plasma-derived therapies franchise (Gammagard, Hyqvia, HyperRAB), making Takeda a top-3 global IVIG competitor. Direct overlap with ADMA in immune globulin products for PI and hepatitis B prophylaxis.
• Kedrion Biopharma: Italy-based plasma-derived therapies company marketing IVIG and hepatitis B immune globulin products. Direct competitor in hyperimmune and standard IVIG categories; previous employer of ADMA board member Lawrence Guiheen provides direct industry context.

Emerging players

• Catalent: Major CDMO offering sterile fill-finish and aseptic manufacturing services — directly competing with ADMA's contract manufacturing revenue stream. Comparable technology investment in advanced biologics manufacturing capacity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about admabio.com